focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 39.00
Ask: 42.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.692%)
Open: 40.50
High: 40.50
Low: 40.50
Prev. Close: 40.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chile Exports

9 Sep 2008 07:00

RNS Number : 9848C
Beximco Pharmaceuticals Ltd
09 September 2008
 



BEXIMCO PHARMACEUTICALS LTD.

9 September 2008

Beximco Pharma commences exports to Chile

Beximco Pharmaceuticals Ltd. ("BPL" or the "Company"), the leading pharmaceutical manufacturer and the largest exporter of pharmaceutical products from Bangladesh, today announces that it has commenced exports to Chile, after receiving marketing authorization for a number of products from "Instituto de Salud Publica de Chile" (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country.

Chile is the sixth largest pharmaceutical market in Latin AmericaIn 2007, the Chilean pharmaceutical market was valued at US$1.5 billion. 

Beximco Pharma CEO Mr. Nazmul Hassan said:

"Our entry into Latin America marks another milestone in the Company's plan to become a global pharmaceutical company. With a market size of around US$40 billion and with a high growth rate, Latin America is considered as one of the biggest pharmaceutical markets and it is strategically important for us in our global expansion programBeing successful in registering our products in Chile will mark our presence in the regionWe continue to seek similar opportunities and are actively working in other Latin American countries." 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, CEO

Tel: +880 2 861 9151, ext.2080

 

Libertas Capital

Aamir Quraishi / Andrew Hardy

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

David Yates / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in DhakaBangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri LankaNepalBhutanVietnamCambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUWANRWSRKRAR
Date   Source Headline
27th Dec 20187:00 amRNSEGM Statement
30th Nov 20187:00 amRNSAGM Notification
30th Nov 20187:00 amRNSEGM Notification
29th Nov 20188:30 amRNSBeximco Pharma wins at Scrip Awards 2018
14th Nov 20187:00 amRNSResults for First Quarter Ended 30 September 2018
7th Nov 20187:00 amRNSResults for the 12 month period ended 30 June 2018
26th Oct 20187:00 amRNSNotification of Preliminary Results and AGM
30th Jul 20187:00 amRNSUS FDA Approves Beximco Pharma's Nadolol Tablets
23rd Jul 20187:00 amRNSCommences export of fourth product to the US
27th Apr 20187:00 amRNS3rd Quarter Results
23rd Apr 20187:00 amRNSCommences Export of Third Product to the US Market
3rd Apr 20187:00 amRNSCompletion of the Acquisition of Nuvista Pharma
30th Jan 20187:00 amRNSHalf Year Results 2017-18
19th Jan 20187:00 amRNSPayment of Cash Dividend
19th Jan 20187:00 amRNSAcquisition of a Majority Stake in Nuvista Pharma
27th Dec 20177:00 amRNSAGM Statement
30th Nov 201710:30 amRNSBeximco Pharma wins at Scrip Awards 2017
23rd Nov 201711:53 amRNSNotice of AGM
14th Nov 20177:00 amRNSResults for First Quarter Ended 30 September 2017
7th Nov 20177:00 amRNSCommencement of Second Product Export to the US
6th Nov 201710:30 amRNSResults for the 12 month period ended 30 June 2017
26th Oct 20177:00 amRNSNotice of Preliminary Results and AGM
6th Oct 20177:00 amRNSSigns a Non-Binding MoU with Nuvista Pharma
2nd Oct 20177:00 amRNSChange of Broker
18th Sep 20177:00 amRNSCommences Export to Canada
25th Jul 20177:00 amRNSFDA approves Beximco Pharma Methocarbamol tablets
28th Apr 20177:00 amRNSFinancial Results for the Third Quarter of 2016-17
27th Jan 20177:00 amRNSHalf year results 2016-17
25th Jan 20177:00 amRNSBeximco Pharma forms JV with BioCare Manufacturing
19th Dec 20167:00 amRNSUS FDA approves Metformin for diabetes control
16th Dec 201610:12 amRNSPayment of Cash Dividend
12th Dec 20161:54 pmRNSStock Dividend Issued and Total Voting Rights
21st Nov 20167:00 amRNSAGM Statement
15th Nov 20167:00 amRNS1st Quarter Results
25th Oct 20167:00 amRNSReceives second product approval from the US FDA
20th Oct 20167:00 amRNSResults for the 18 month period ended 30 June 2016
19th Oct 20167:00 amRNSNotice of AGM
7th Oct 20167:00 amRNSNotification of Preliminary Results and AGM
5th Aug 20167:00 amRNSBeximco Pharma commences export to the US
17th Jun 20167:00 amRNSBeximco Pharma commences export to Kuwait
9th May 20167:00 amRNSFinal Results
6th May 20167:01 amRNSAGM Change and Dividend Update
6th May 20167:00 amRNSChange of Accounting Reference Date
4th May 20167:00 amRNSAmendment to Notification of Preliminary Results
21st Apr 20167:00 amRNSNotification of Preliminary Results and AGM
19th Nov 20157:00 amRNSUS FDA approval to manufacture blood pressure drug
27th Oct 20157:00 amRNS3rd Quarter Results
24th Jul 20157:00 amRNSHalf Yearly Report
13th Jul 201510:53 amRNSPayment of Cash Dividend
26th Jun 20157:00 amRNSStock Dividend Issued and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.